CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation

Soler, Meritxell; Miñana, Gema; Santas, Enrique; Núñez, Eduardo; Espriella, Rafael de la; Valero, Ernesto; Bodı́, Vicente; Chorro, Francisco J.; Fernández‐Cisnal, Agustín; D'Ascoli, Giulio; Martí-Cervera, Jorge; Sanchís, Juan; Bayés‐Genís, Antoni; Núñez, Julio

doi:10.1016/j.ijcard.2020.03.027

Cited by 35 publications

(50 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, in some clinical scenarios characterized by overt systemic congestion and right ventricular dysfunction [e.g. patients with severe functional tricuspid regurgitation (TR)], CA125 may outperform NT‐proBNP in predicting long‐term mortality 30 . A recent study of 2961 patients discharged from AHF demonstrated a differential mortality risk association of CA125 and NT‐proBNP across TR severity.…”

Section: Ca125 and Natriuretic Peptides: Different But Complementarymentioning

confidence: 99%

“…A recent study of 2961 patients discharged from AHF demonstrated a differential mortality risk association of CA125 and NT‐proBNP across TR severity. Higher CA125 values were associated with elevated risk in the whole sample; however, the effect was greater in patients with severe TR 30 . Thus, we envision the complementary use of both markers for assessing the degree of each heart side participation, where CA125 and NPs mirrored the right and left‐sided HF, respectively.…”

Section: Ca125 and Natriuretic Peptides: Different But Complementarymentioning

confidence: 99%

See 1 more Smart Citation

Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review

Núñez

Espriella

Miñana

et al. 2021

European J of Heart Fail

Self Cite

104

View full text Add to dashboard Cite

Congestion explains many of the signs and symptoms of acute heart failure (AHF) and disease progression. However, accurate quantification of congestion is challenging in daily practice. Antigen carbohydrate 125 (CA125) or mucin 16 (MUC16), a large glycoprotein synthesized by mesothelial cells, has emerged as a reliable proxy of congestion and inflammation in patients with heart failure (HF). In AHF syndromes, CA125 is strongly associated with right‐sided HF parameters and a higher risk of adverse clinical events beyond standard prognostic factors, including natriuretic peptides. Furthermore, CA125 has the potential for both monitoring and guide HF treatment following a decompensated HF event. The wide availability of CA125 in most clinical laboratories, together with its standardized measurement and reduced cost, makes this marker attractive for routine use in decompensated HF. Further research is required to understand better its biological role and its promising utility as a tool to guide decongestive therapy in HF.

show abstract

Section: Ca125 and Natriuretic Peptides: Different But Complementarymentioning

confidence: 99%

Section: Ca125 and Natriuretic Peptides: Different But Complementarymentioning

confidence: 99%

Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review

Núñez

Espriella

Miñana

et al. 2021

European J of Heart Fail

Self Cite

104

View full text Add to dashboard Cite

show abstract

“…The reverse rationale has also been suggested, reporting that certain tumour biomarkers could predict CVD severity and prognosis. CA 125 known as a biomarker for ovarian cancer and several haematological malignancies has been shown as a promising CV biomarker in diverse CVD [ 113 , 114 ] . Furthermore, other tumour biomarkers, such as CYFRA 21-1, CEA and Ca 19–9, demonstrated a prognostic value, especially in patients with severe HF [ 115 ].…”

Section: Shared Prognostic Factorsmentioning

confidence: 99%

A new classification of cardio-oncology syndromes

et al. 2021

View full text Add to dashboard Cite

Increasing evidence suggests a multifaceted relationship exists between cancer and cardiovascular disease (CVD). Here, we introduce a 5-tier classification system to categorize cardio-oncology syndromes (COS) that represent the aspects of the relationship between cancer and CVD. COS Type I is characterized by mechanisms whereby the abrupt onset or progression of cancer can lead to cardiovascular dysfunction. COS Type II includes the mechanisms by which cancer therapies can result in acute or chronic CVD. COS Type III is characterized by the pro-oncogenic environment created by the release of cardiokines and high oxidative stress in patients with cardiovascular dysfunction. COS Type IV is comprised of CVD therapies and diagnostic procedures which have been associated with promoting or unmasking cancer. COS Type V is characterized by factors causing systemic and genetic predisposition to both CVD and cancer. The development of this framework may allow for an increased facilitation of cancer care while optimizing cardiovascular health through focused treatment targeting the COS type.

show abstract

“…[ 45 , 46 ] In line with this, CA125 was shown to be associated with well-established laboratory proxies of clinical congestion, such as bio-adrenomedullin and NT-proBNP. [ 47 ] In fact, one study showed that in clinical scenarios marked by systemic congestion and right ventricular dysfunction, CA125 may even outperform NT-proBNP in predicting mortality. [ 48 ]…”

Section: Ca125 As An Indicator Of Congestion In Heart Failure and Its Relationship With Haemodynamic And Echocardiographic Parametersmentioning

confidence: 99%

“…Many study groups investigated the prognostic role of CA125 in patients with acute and chronic HF in terms of death and HF readmission in various clinical settings. [ 44 , 47 , 51 , 53 , 55 , 56 , 59 – 67 ] Apart from a randomised clinical trial by Núñez et al (CHANCE-HF), most of the studies were designed as observational studies, and they largely included patients with acute HF. [ 61 ] In addition, only one study reported on the prognostic role of CA125 in patients with HF with preserved ejection fraction (HFpEF) exclusively.…”

Section: Ca125 As a Prognostic Factor Of Mortality And Readmissions Due To Heart Failurementioning

confidence: 99%

Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure

et al. 2021

View full text Add to dashboard Cite

Because heart failure (HF) is more lethal than some of the common malignancies in the general population, such as prostate cancer in men and breast cancer in women, there is a need for a cost-effective prognostic biomarker in HF beyond natriuretic peptides, especially concerning congestion, the most common reason for the hospitalisation of patients with worsening of HF. Furthermore, despite diuretics being the mainstay of treatment for volume overload in HF patients, no randomised trials have shown the mortality benefits of diuretics in HF patients, and appropriate diuretic titration strategies in this population are unclear. Recently, carbohydrate antigen (CA) 125, a well-established marker of ovarian cancer, emerged as both a prognostic indicator and a guide in tailoring decongestion therapy for patients with HF. Hence, in this review the authors present the molecular background regarding the role of CA125 in HF and address valuable clinical aspects regarding the relationship of CA125 with both prognosis and therapeutic management in HF.

show abstract

CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation

Cited by 35 publications

References 31 publications

Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review

Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review

A new classification of cardio-oncology syndromes

Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure

Contact Info

Product

Resources

About